Secukinumab biosimilar, human IL17A monoclonal antibody

Recombinant fully human IgG1 monoclonal antibody.
Isotype: Human IgG1 kappa.
Source: The monoclonal antibody secukinumab biosimilar was produced in the mammalian cells.
Specificity/Sensitivity: The monoclonal antibody secukinumab biosimilar specifically binds to the human IL17A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by secukinumab.
Form of Antibody: 0.2 uM filtered solution, pH 5.8, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade secukinumab biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.